Cardiovascular Outcomes Associated with SGLT2 Inhibitor Therapy in Patients with Type 2 Diabetes Mellitus and Cancer: a Systematic Review and Meta-analysis

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2024 May 21

PMID 38773486

Authors

Hsiao-Huai Kuo

Kuang-Te Wang

Hsin-Hao Chen

Zih-Yin Lai

Po-Lin Lin

Yung-Jen Chuang

Lawrence Yu-Min Liu

Affiliations

Soon will be listed here.

Abstract

Background: Cancer patients with diabetes are at increased risk for cardiovascular diseases due to common risk factors and well-documented drug-associated cardiotoxicity. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown cardiovascular benefits in patients with diabetes, but their effects on cancer patients remain unclear. This study aimed to evaluate the cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with concomitant diabetes and cancer.

Methods: We conducted a systematic review and meta-analysis of cohort studies comparing cardiovascular outcomes between cancer patients with diabetes receiving SGLT2 inhibitors and those not receiving SGLT2 inhibitors. PubMed, Embase, and the Cochrane Library were searched from inception to February 29, 2024. The primary outcome was all-cause mortality, and the secondary outcomes were heart failure hospitalization, and adverse events. Random-effect models were used to calculate pooled risk ratios (RR) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were conducted to identify potential sources of heterogeneity and explore the effect of SGLT2 inhibitors on mitigating cardiotoxicity.

Results: Nine cohort studies involving 82,654 patients were included. SGLT2 inhibitor use was associated with a significantly lower risk of all-cause mortality (RR 0.46, 95% CI 0.31-0.68, P < 0.0001; I = 98%) and heart failure hospitalization (RR 0.49, 95% CI 0.30-0.81, P = 0.006; I = 21%) compared to non-use. The mortality benefit remained significant in patients receiving anthracycline chemotherapy (RR 0.50, 95% CI 0.28-0.89, P = 0.02; I = 71%). SGLT2 inhibitor use was also associated with a lower risk of sepsis (RR 0.32, 95% CI 0.23-0.44, P < 0.00001; I = 0%) and no increased risk of diabetic ketoacidosis (RR 0.66, 95% CI 0.20-2.16, P = 0.49; I = 0%).

Conclusions: SGLT2 inhibitor therapy is associated with lower risks of all-cause mortality and heart failure hospitalization in patients with concomitant diabetes and cancer. These findings suggest that SGLT2 inhibitors may offer cardiovascular benefits in this high-risk population. Randomized controlled trials are needed to validate these findings and evaluate the safety and efficacy of SGLT2 inhibitors in specific cancer types and treatment regimens.

References

Luo J, Hendryx M, Dong Y . Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival. Br J Cancer. 2023; 128(8):1541-1547. PMC: 10070339. DOI: 10.1038/s41416-023-02177-2. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Lytvyn Y, Bjornstad P, Udell J, Lovshin J, Cherney D . Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017; 136(17):1643-1658. PMC: 5846470. DOI: 10.1161/CIRCULATIONAHA.117.030012. View

Jawa Z, Perez R, Garlie L, Singh M, Qamar R, Khandheria B . Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore). 2016; 95(44):e5195. PMC: 5591107. DOI: 10.1097/MD.0000000000005195. View

Chiang C, Chiang C, Chiang C, Ma K, Peng C, Hsia Y . Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2022; 109(6):470-477. PMC: 10037540. DOI: 10.1136/heartjnl-2022-321545. View

Hendryx M, Dong Y, Ndeke J, Luo J . Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS One. 2022; 17(9):e0274519. PMC: 9467321. DOI: 10.1371/journal.pone.0274519. View

Perelman M, Brzezinski R, Waissengrin B, Leshem Y, Bainhoren O, Rubinstein T . Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardiooncology. 2024; 10(1):2. PMC: 10782769. DOI: 10.1186/s40959-023-00199-6. View

Villani L, Smith B, Marcinko K, Ford R, Broadfield L, Green A . The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016; 5(10):1048-1056. PMC: 5034684. DOI: 10.1016/j.molmet.2016.08.014. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

10.

Mohite P, Lokwani D, Sakle N . Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations. Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):6107-6119. DOI: 10.1007/s00210-024-03021-x. View

11.

Yeh E, Bickford C . Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009; 53(24):2231-47. DOI: 10.1016/j.jacc.2009.02.050. View

12.

Gongora C, Drobni Z, Silva T, Zafar A, Gong J, Zlotoff D . Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. JACC Heart Fail. 2022; 10(8):559-567. PMC: 9638993. DOI: 10.1016/j.jchf.2022.03.006. View

13.

Yeh T, Hsu M, Hsu H, Tsai M, Jhuang J, Chiang C . Risk of cardiovascular diseases in cancer patients: A nationwide representative cohort study in Taiwan. BMC Cancer. 2022; 22(1):1198. PMC: 9677651. DOI: 10.1186/s12885-022-10314-y. View

14.

Meijers W, de Boer R . Common risk factors for heart failure and cancer. Cardiovasc Res. 2019; 115(5):844-853. PMC: 6452432. DOI: 10.1093/cvr/cvz035. View

15.

Mecinaj A, Gulati G, Heck S, Holte E, Fagerland M, Larsen A . Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology. 2021; 7(1):33. PMC: 8474901. DOI: 10.1186/s40959-021-00115-w. View

16.

Nicolazzi M, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R . Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018; 22(7):2175-2185. DOI: 10.26355/eurrev_201804_14752. View

17.

Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C . SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J. 2019; 67(1):99-106. DOI: 10.1507/endocrj.EJ19-0428. View

18.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

19.

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

20.

Huang Y, Chen W, Jao A, Chen M, Shia B, Wu S . Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes. Diabetes Metab. 2023; 50(1):101500. DOI: 10.1016/j.diabet.2023.101500. View